Mereo BioPharma (MREO)

• Market cap: $49.4M
• 1 day: -0.19%
• 5 days: 0.36%
• 1 month: 30.33%
• 3 months: -12.03%
• 6 months: -83.89%
• Year to date: -39.38%
• 1 year: -89.22%
• 5 years: -90.76%
• 10 years: -95.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Employees: 39